Clinical trial NCT00392821: Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
Official title: Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Kidney Cancer
Lead sponsor: SCRI Development Innovations, LLC
Sponsor class: OTHER
Collaborators: name: Novartis
name: Bayer
First posted: 2006-10-26
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is being done in 2 parts. The first part is to determine the dose of RAD001 that should be used in combination with sorafenib. The second part is using the above determined dose of RAD001 in combination with sorafenib to see how effective these 2 drugs are against advanced kidney cancer.

Participants will be asked to keep a pill diary.

Detailed description: The drugs used in this trial are called targeted drugs as they target specific activities that are carried out by cancer cells that make them grow and spread. Sorafenib is an approved drug for the treatment of advanced kidney cancer. RAD001 is an experimental drug that has been used in other research studies with other types of cancer. In this trial, the use of RAD001 and sorafenib together for the treatment of kidney cancer is experimental. In the Phase I portion of this study 13-16 patients will be treated with the same dose of sorafenib and different doses of RAD001. The purpose is to see what is a safe dose of RAD001 when combined with sorafenib in the treatment of kidney cancer. Once this dose of RAD001 is determined, about 65 more patients will be treated to see how effective this combination of drugs is against this kidney cancer.

Both of these drugs are taken by mouth. Sorafenib will be taken twice a day. RAD001 is taken by mouth weekly. Patients will be able to continue treatment as long as their disease does not worsen or side effects become intolerable.

Eligibility criteria: Inclusion Criteria:

* Clinically documented metastatic or unresectable locally recurrent clear cell renal carcinoma
* Previous removal of kidney except if the size of the tumor was less than 5 cm or there was extensive liver or bone metastasis
* May have had no prior chemotherapy or up to 1 prior treatment regimen with immunotherapy or chemotherapy
* Performance status of 0-1
* Measurable disease
* Adequate liver, renal, and bone marrow function
* Must be able to give written informed consent
* Women able to become pregnant must have a negative pregnancy test
* Must be 18 or over
* Must be able to swallow pills

Exclusion Criteria:

* Prior treatment with sorafenib or m-TOR inhibitors
* History of acute MI within the last 6 months
* Active brain metastasis or patients with meningeal metastases
* Prior treatment for another cancer in the last 5 years
* Prior bleeding problems; coughing up or vomiting blood
* Non-healing wounds, ulcer, or long bone fracture
* Chronic use of systemic steroids or immunosuppressive agents
* Uncontrolled hypertension

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have. You can then decide if you wish to participate.

Primary outcomes:
measure: Overall Response Rate (ORR) of Patients Treated at MTD/Phase II Dose Level
timeFrame: 18 months
Secondary outcomes:
measure: Progression-Free Survival for Patients Treated at MTD/Phase II Dose Level
timeFrame: 18 months
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Florida Hospital Cancer Institute
state: Florida
city: Gainesville
country: United States
facility: Northeast Georgia Medical Center
state: Georgia
city: Marietta
country: United States
facility: Wellstar Cancer Research
state: Georgia
city: Louisville
country: United States
facility: Baptist Hospital East
state: Kentucky
city: Louisville
country: United States
facility: Norton Cancer Institute
state: Kentucky
city: Kansas City
country: United States
facility: Research Medical Center
state: Missouri
city: Morristown
country: United States
facility: Hematology Oncology Associates of Northern NJ
state: New Jersey
city: Cincinnati
country: United States
facility: Oncology Hematology Care
state: Ohio
city: Columbia
country: United States
facility: South Carolina Oncology Associates, PA
state: South Carolina
city: Spartanburg
country: United States
facility: Spartanburg Regional Medical Center
state: South Carolina
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
Study officials:
affiliation: SCRI Development Innovations, LLC
name: John D Hainsworth, MD
role: PRINCIPAL_INVESTIGATOR
References: